IDBS, the leading worldwide provider of research data management and analytics solutions to R&D organizations, today announced that it has formed a new global unit dedicated to extending the growing use of its award-winning products and solutions in the healthcare sector. With the healthcare business unit, IDBS will allocate resources to invest in and develop, deliver, and manage healthcare and translational medicine-focused solutions, while enabling the company to retain its strong commitment to enterprise software across life sciences and industrial R&D.
IDBS, long recognized for its enterprise software solutions for the life sciences domain, has become an early leader in the development of informatics platforms and managed services for the growing global personalized and translational medicine market. Consortia of primary healthcare organizations, pharmaceutical companies and clinical researchers looking to understand the impact of genetics on disease and treatment are requiring solutions that provide in-depth analysis of highly complex, distributed data.
IDBS' deep domain knowledge and data management and analytics technologies have been widely adopted from bench to bedside at numerous primary healthcare organizations, pharmaceutical, biotech and diagnostic companies, and medical research groups, including Dana-Farber Cancer Institute, Children's Hospital of Philadelphia, Barts and the London NHS trust, and Celera, and continue to evolve to meet the needs of new therapeutic areas, clinical integration and genomic analysis technologies. It is specifically to address the needs of this growing translational medicine market that IDBS has launched the new healthcare unit.
"Today's announcement represents a natural evolution of our capabilities and builds on the knowledge and expertise gained from our years of work in research, preclinical and clinical areas with leading commercial, academic and healthcare groups," said Neil Kipling, founder and CEO of IDBS. "Our intention with the healthcare unit is twofold: First, we can capitalize on our proven leadership and in-depth knowledge of translational medicine to extend our solution to improve the understanding and use of healthcare data. Second, by creating a separate healthcare unit, we can maintain our fundamental emphasis on the enterprise platforms within pharmaceuticals and R&D organizations that are the foundation of IDBS."
About the IDBS Healthcare Unit The IDBS Healthcare Unit is dedicated to the advancement of personalized medicines and improved patient outcomes through the delivery of advanced translational medicine and biomarker research informatics that bridge the worlds of clinical, molecular and image data. Our sophisticated data management and analytics solutions underpin improved disease understanding, more effective diagnosis and treatment selection. By delivering the enterprise infrastructures and managed services required for translational and biomarker studies, IDBS is revolutionizing research environments to enhance innovation, accelerate research and improve data and research quality. By working with leading organizations from bench to bedside, IDBS is enabling collaboration across the health science ecosystem.
About IDBSIDBS is a unique, global supplier of innovative data management and first-in-class analytics solutions which increase efficiency, reduce costs and improve the productivity of healthcare R&D organizations. Multinational pharmaceutical companies, major public-private healthcare partnerships, global leaders in academic study and high tech companies employ IDBS as a strategic supplier of scientific informatics and business process improvement solutions. IDBS is clearly differentiated by its unique combination of deep domain knowledge across the entire R&D sector: from the examination of the human genome at the scientist's bench, through the clinic, to translational medicine initiatives and pay-for-performance healthcare monitoring. IDBS solutions support the protection of intellectual property (IP) and the requirements for data quality and security demanded under Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and HL7 (Health Level) standards.
IDBS is a private company, founded in 1989 and headquartered in Guildford, UK. IDBS has worldwide consulting and support presence, with U.S. offices in California, New Jersey and Massachusetts, the EU, Australia and China. Find out more at www.idbs.com (http://www.idbs.com) .